热门资讯> 正文
MediWound获得烧伤治疗的儿科适应症NexoBrid
2024-08-19 00:49
- The U.S. FDA has approved use of MediWound's (NASDAQ:MDWD) burn treatment NexoBrid in pediatric patients as young as newborns.
- NexoBrid (anacaulase) is intended for removal of eschar -- dead tissue that forms over healthy skin -- for patients with deep partial- and/or full-thickness thermal burns.
- Approval was based on phase 3 data from hospitalized pediatric patients, and pediatric data from other phase III and phase II trials conducted during NexoBrid's development.
More on MediWound
- MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
- MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
- MediWound Q2 2024 Earnings Preview
- MediWound rises on €16.25 million funding from European Innovation Council
- Seeking Alpha’s Quant Rating on MediWound
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
